Nimesh Patel: Understanding Plasmapheresis – A Clinical Overview
Nimesh Patel, National Board Of Examinations in Medical Sciences at CKS Hospitals, shared a post on LinkedIn:
“Understanding Plasmapheresis: A Clinical Overview
Plasmapheresis—also known as therapeutic plasma exchange (TPE)—is a critical procedure used to remove large molecules such as pathogenic autoantibodies, immune complexes, or toxins from a patient’s plasma.
When the removal of circulating substances is required to halt or reverse disease progression, TPE becomes an essential intervention.
Key Clinical Indications
- Neurology: Myasthenia gravis, Guillain-Barré syndrome, and Chronic inflammatory demyelinating polyneuropathy (CIDP).
- Hematology: Thrombotic thrombocytopenic purpura (TTP) and Hyperviscosity syndrome.
- Nephrology: Anti-GBM disease (Goodpasture syndrome) and ANCA-associated vasculitis.
- Immunology and Other: Transplant rejection (ABO-incompatible) and Catastrophic antiphospholipid syndrome.
Potential Complications
While generally well-tolerated, the extracorporeal circuit and plasma replacement process carry inherent risks.
- Hypocalcemia: Commonly caused by citrate toxicity used for anticoagulation, which can lead to tingling, muscle cramps, or cardiac arrhythmias.
- Hypotension: Often related to volume shifts or patient sensitivity to the procedure.
- Infection/Access-related: Risks such as bacteremia or thrombosis associated with central venous catheter placement.
- Coagulopathy: Increased bleeding risk resulting from the removal of clotting factors.
- Allergic Reactions: Sensitivity to replacement fluids (e.g., albumin or fresh frozen plasma), ranging from mild urticaria to anaphylaxis.
Educational Disclaimer:
This content is intended for educational purposes only. Clinical decisions should always be individualized based on patient condition, clinical judgment, and institutional protocols.”

Stay updated with Hemostasis Today.
-
Aug 26, 2026, 16:53Chokri Ben Lamine: Antiphospholipid Syndrome After Kidney Transplantation
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal